Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations
Janet Glassford(London Cancer), Kwee Yong(CRUK Lung Cancer Centre of Excellence)
Cited by 14
Related Papers
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Guidelines for the diagnosis and management of multiple myeloma 2011
|British Journal of Haematology|2011|305
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266